Tunicamycin produces a concentration- and time-dependent decrease in cell viability in SH-SY5Y cells concomitant with caspase-3 activation. by Arindam P. Ghosh (317870)

“…(F) Tunicamycin (1µM) treatment of SH-SY5Y cells upregulated markers of the UPR: BiP, phospho eIF2α and CHOP on immunoblotting. Data points represent mean ± SEM, with n = 6.…”

Mutation on residues A160 and G161 of Rtg2p ATP-binding loop decreases retrograde signaling, but not affect yeast longevity. by Rafaela Maria Rios-Anjos (4003220)

Measurement of proteinuria levels in CG, NG, NVG, and NVRG. by Jian-feng Li (8667645)

Tubastatin decreases TGF-β1-induced phosphorylation of Akt, likely by restoring the association of Akt and PHLPP. by Shigeki Saito (560645)

Tryptophan and metabolite alterations in response to a control diet or a diet containing MCOA. by Natalie E. Diether (16705804)

Nsp8 decreases antiviral immune and inflammatory responses and promotes SARS-CoV-2 infection. by Xiaolin Zhang (246784)

Mean values and 95% confidence intervals for recovery time, Average NN Interval (AVNN); Standard Deviation of NN Intervals (SDNN), Low Frequency/ High Frequency Ratio (LF/HF); and... by Robert Trybulski (10998702)

Well-watered (WW) <i>C</i>. <i>paniculatum</i> plants after drought stress (DS) for 10 days (T1, T2 and T3) and re-watering (RW) following DS for 10 days (only shows a T2 plant aft... by Jie He (132999)

Temporal profiles of the key BO-NN features. by Julia Berezutskaya (9080269)

“…Right plot show the gradual decrease in the TM tuning for the features highlighted in <b>c</b> as well as the gradual increase in the temporal response profile (i.e. optimal shifts for the prediction of the key BO-NN features using Praat features shown in <b>a</b>). …”

Decrease of junctional zone area in low protein placentas at E10.5, E17.5 and E18.5. by Paula N. Gonzalez (372538)

Source data for Fig 1. by Rahsan Erdem (11726357)

Source data for Fig 2. by Rahsan Erdem (11726357)

Source data for Fig 3. by Rahsan Erdem (11726357)

Demographics and baseline characteristics of the safety population. by Rahsan Erdem (11726357)

Grading of stool consistency and diarrhea severity. by Rahsan Erdem (11726357)

Secondary efficacy endpoints for the modified intent-to-treat population. by Rahsan Erdem (11726357)

Source data for S1 and S2 Figs. by Rahsan Erdem (11726357)

Consolidated Standards for Reporting of Trials flow diagram. by Rahsan Erdem (11726357)

Diarrheal disease severity by treatment group for the modified intent-to-treat population. by Rahsan Erdem (11726357)

iOWH032 inhibits cholera toxin-induced secretion in a mouse closed-loop model. by Rahsan Erdem (11726357)